

JUN 07 2001

TECH CENTER 1600/2900

FORM PTO-1449/A and B (Modified)		APPLICATION NO.:09/768,012	ATTY. DOCKET NO.: C1040/7010
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: January 22, 2001	
		APPLICANT: Davis and McCluskie	
		GROUP ART UNIT: 1632	EXAMINER: Not yet assigned
Sheet			



U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYY
		Number	Kind Code		

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/Country	Number	Kind Code			

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.
	C1	Huang, et al., "Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysaccharide, and heat-inactivated bacteria", <i>Infection and Immunity</i> , 67(12):6257-6263 (1999)
	C2	Kataoka, , et al., "Antitumor activity of synthetic oligonucleotides with sequences from cDNA encoding proteins of <i>Mycobacterium bovis</i> BCG", <i>Jpn. J. Cancer Res.</i> , 83:244-247 (1992)
	C3	Kline, et al., "CpG oligodeoxynucleotides do not require T _{HI} cytokines to prevent eosinophilic airway inflammation in a murine model of asthma", <i>J. Allergy Clin. Immunol.</i> , 1258-64 (1999)
	C4	Krieg AM et al, "Phosphorothioate Oligodeoxynucleotides: Antisense or Anti-Protein?", <i>Antisense Research and Development</i> , (1995), 5:241
	C5	McIntyre KW et al., A sense phosphorothioate oligonucleotide directed to the initiation codon of transcription factor NF-kappa B p65 causes sequence-specific immune stimulation. <i>Antisense Res Dev</i> 3(4):309-22, Winter 1993.
	C6	Messina et al., Stimulation of <i>in vitro</i> Murine Lymphocyte Proliferation by Bacterial DNA. <i>J. Immunol.</i> , Vol. 147, 6:1759-1764, September 15, 1991.
	C7	Robertson, D., "Business & Regulatory News: Crohn's trial shows the pros of antisense", <i>Nature Biotechnology</i> , 15:209 (1997)
	C8	Sun, et al., "Mitogenicity of DNA from different organisms for murine B cells", <i>J. of Immunol.</i> , 159:3119-3125 (1997)
	C9	Tokunaga T et al., Synthetic Oligonucleotides with Particular Base Sequences form the cDNA Encoding Proteins of <i>Myobacterium bovis</i> BCG Induce Interferons and Activate Natural Killer Cells, <i>Microbiol. Immunol.</i> , Vol. 36, 1:55-66, 1992.

EXAMINER	<i>DN</i>	DATE CONSIDERED	8/11/02
----------	-----------	-----------------	---------

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/316,199, filed May 21, 1999, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE - Must provide a copy of any patent, publication, other information listed, even if it was previously submitted to, or cited by, the U.S. Patent Office in an earlier application, unless the earlier application is identified by the IDS and is relied upon for an earlier filing date under 35 U.S.C. §120, and the copy was provided in the earlier application.]

O I P E 1
JUL 02 2001

PATENT & TRADEMARK OFFICE

FORM PTO-1449(Modified)	ATTY. DOCKET NO.: C1040/7010	SERIAL NO.: 09/768,012
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Heather L. Davis and Michael J. McCluskie	
	FILING DATE: January 22, 2001	GROUP: 1632

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	FILING DATE If Appropriate

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes No
1	B1	WO 98/40100 A1	09.17.98	PCT Application	A61K	39/39	
2	B2	WO 99/52549 A1	10.21.99	PCT Application	A61K	39/39	

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

1	C10	Horner, et al., "Muscosal adjuvanticity of immunostimulatory DNA sequences", Springer Semin. Immunopathol., 22(1/2):133-146, 2000
	C11	McCluskie, et al., "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice", J. Immunol., 161(9): 4463-4466, 1998 (published erratum appears in J. Immunol. 162(5):3103, 1999)
	C12	McCluskie, et al., "CpG DNA as mucosal adjuvant" Vaccine, 18:231-237, 1999
	C13	Chu, et al., "CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (TH1) immunity", J. Exp. Med., 186(10):1632-1631, 1997
	C14	Klinman, et al., "CpG motifs as immune adjuvants", Vaccine, 17:19-25, 1999
	C15	McCluskie, et al., "The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants", Vaccine, 19(17-19): 2657-2660, 2001
1	C16	McCluskie, et al., "Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants" Vaccine, 19(4-5):413-422, 2001

EXAMINER	<i>D. M.</i>	DATE CONSIDERED	<i>8/1/02</i>
----------	--------------	-----------------	---------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant



12

FORM PTO-1449/A and B (Modified)

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Sheet 1 of 5

APPLICATION NO.: 09/768,012

ATTY. DOCKET NO.: C1040/7010

FILING DATE: January 22, 2001

APPLICANT: Davis et al.

GROUP ART UNIT: 1632

EXAMINER: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner's Initials#	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
DR	A1	5,541,164	B1	Carson et al.	07/30/1996
	A2	5,561,064	B1	Marquet et al.	10/01/1996
	A3	5,567,604	B1	Rando et al.	10/22/1996
	A4	5,580,859	B1	Felgner et al.	12/03/1996
	A5	5,589,466	B1	Felgner et al.	12/31/1996
	A6	5,663,153	B1	Hutcherson et al.	09/02/1997
	A7	5,679,647	B1	Carson et al.	10/21/1997
	A8	5,693,622	B1	Wolff et al.	12/02/1997
	A9	5,703,055	B1	Felgner et al.	12/30/1997
	A10	5,707,812	B1	Horn et al.	01/13/1998
	A11	5,723,335	B1	Hutcherson et al.	03/03/1998
	A12	5,773,570	B1	Carson et al.	06/30/1998
	A13	5,780,448	B1	Davis	07/14/1998
	A14	5,804,566	B1	Carson et al.	09/08/1998
	A15	5,830,877	B1	Carson et al.	11/03/1998
	A16	5,843,943	B1	Carson et al.	12/01/1998
	A17	5,849,719	B1	Carson et al.	12/15/1998
	A18	5,972,346	B1	Hauser et al.	10/26/1999
	A19	5,985,847	B1	Carson et al.	11/16/1999
	A20	6,013,639	B1	Peyman et al.	01/11/2000
	A21	6,090,791	B1	Sato et al.	07/18/2000
	A22	6,121,434	B1	Peyman et al.	09/19/2000
	A23	6,147,123	B1	Chojkier et al.	11/14/2000
	A24	6,153,200	B1	Carson et al.	11/28/2000
	A25	6,174,872	B1	Carson et al.	01/16/2001
	A26	6,194,388	B1	Krieg et al.	02/27/2001
	A27	6,207,646	B1	Krieg et al.	03/27/2001
	A28	6,214,571	B1	Carrera et al.	04/10/2001
	A29	6,214,804	B1	Felgner et al.	04/10/2001
	A30	6,214,806	B1	Krieg et al.	04/10/2001
	A31	6,218,371	B1	Krieg et al.	04/17/2001
	A32	6,239,116	B1	Krieg et al.	05/29/2001

FOREIGN PATENT DOCUMENTS

Examiner's Initials#	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
DR	B3	EP	0 302 758	B1	New England Medical Center Hospitals	02/08/1989	

558225.1

DR

8/11/02



09/168,012

	B4	WO	90/11092	A1	Vical, Inc. etc.	10/04/1990	
	B5	WO	91/12811	A1	ISIS Pharmaceuticals, Inc.	09/05/1991	
	B6	EP	0 468 520	A3	Mitsui Toatsu Chemicals, Inc.	01/29/1992	
	B7	WO	92/03456	A1	ISIS Pharmaceuticals, Inc.	03/05/1992	
	B8	WO	92/18522	A1	The Salk Institute for Biological Studies	10/29/1992	
	B9	WO	92/21353	A1	Genta, Inc.	12/10/1992	
	B10	WO	94/19945	A1	ISIS Pharmaceuticals, Inc.	09/15/1994	
	B11	WO	94/29469	A2	_____	12/22/1994	
	B12	WO	95/05853	A1	Regents of the University of CA	03/02/1995	
	B13	WO	95/26204	A1	ISIS Pharmaceuticals, Inc.	10/ /1995	
	B14	WO	96/02555	A1	University of IA Research Foundation	02/01/1996	
	B15	WO	96/13277	A1	Regents of the University of CA	05/09/1996	
	B16	WO	96/14074	A1	Regents of the University of CA	05/17/1996	
	B17	WO	96/24380	A1	ICN Pharmaceuticals, Inc.	08/15/1996	
	B18	WO	96/35782	A1	Applied Research Systems	11/14/1996	
	B19	WO	97/00957	A1	President & Fellows of Harvard College	01/09/1997	
	B20	WO	97/28259	A1	Regents of the University of CA	08/07/1997	
	B21	WO	98/14210	A1	Regents of the University of CA	04/09/1998	
	B22	WO	98/16247	A1	Regents of the University of CA	04/23/1998	
	B23	WO	98/18810	A1	University of IA Research Foundation	05/07/1998	
	B24	WO	98/29430	A1	ICN Pharmaceuticals, Inc.	07/09/1998	
	B25	WO	98/32462	A1	Wagner et al.	07/30/1998	
	B26	WO	98/37919	A1	University of IA Research Foundation	09/03/1998	
	B27	WO	98/52581	A1	Ottawa Civic Hospital Loeb Research	11/26/1998	
	B28	WO	98/55495	A2	Dynavax Technologies Corp.	12/10/1998	
	B29	WO	98/55609	A1	Regents of the University of CA	12/10/1998	
	B30	WO	99/11275	A2	Regents of the University of CA	03/11/1999	
	B31	WO	99/51259	A2	University of IA Research Foundation	10/14/1999	
	B32	WO	99/56755	A1	University of IA Research Foundation etc.	11/11/1999	
	B33	WO	99/58118	A2	CpG ImmunoPharmaceuticals, Inc. etc.	11/18/1999	
	B34	WO	99/61056	A2	_____	12/02/1999	
	B35	WO	99/62923	A2	Dynavax Technologies Corp.	12/09/1999	
	B36	WO	00/06588	A1	University of IA Research Foundation etc.	02/10/2000	
	B37	WO	00/14217	A2	CpG ImmunoPharmaceuticals, Inc.	03/16/2000	
	B38	WO	00/16804	A1	Dynavax Technologies Corp.	03/30/2000	
	B39	WO	00/20039	A1	Regents of the University of CA	04/13/2000	
	B40	WO	00/62787	A1	Regents of the University of CA	10/26/2000	
	B41	WO	00/67023	A1	CpG ImmunoPharmaceuticals etc.	11/09/2000	
	B42	WO	00/69861	A1	Regents of the University of CA	11/23/2000	
	B43	WO	01/02007	A1	Regents of the University of CA	01/11/2001	
	B44	WO	01/12223	A2	Dynavax Technologies Corp.	02/22/2001	
	B45	WO	01/22972	A2	University of IA Research Foundation etc.	04/05/2001	
	B46	WO	01/22990	A2	Coley Pharmaceutical Group, Inc. etc.	04/05/2001	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials#	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
A	C17	ANDERSON, W.F., "Human gene therapy", <i>Science</i> , May 8, 1992, Pages 808-813, Vol. 256(5058)	

DEC 05



69768,012


Q	C18	BALLAS, Z. et al., "Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA", <i>J. Immunol.</i> , September 1, 1996, Pages 1840-1845, Vol. 157, No. 5, The American Association of Immunologists	
	C19	BENIMETSKAYA, L. et al., "Formation of a G-tetrad and higher order structures correlates with biological activity of the RelA (NF- κ B p65) 'antisense' oligodeoxynucleotide", <i>Nucleic Acids Res.</i> , July 1, 1997, Pages 2648-2656, Vol. 25, No. 13, Oxford University Press	
	C20	BENIMETSKAYA, L. et al., "Mac-1 (CD11b/CD18) is an oligodeoxynucleotide-binding protein", <i>Nat. Med.</i> , April 1997, Pages 414-420, Vol. 3, No. 4	
	C21	BISHOP, J.S. et al., "Intramolecular G-quartet motifs confer nuclease resistance to a potent anti-HIV oligonucleotide", <i>J. Biol. Chem.</i> , March 8, 1996, Pages 5698-5703, Vol. 271, No. 10, The American Society for Biochemistry and Molecular Biology, Inc. USA	
	C22	BURGESS, T.L. et al., "The antiproliferative activity of c-myb and c-myc antisense oligonucleotides in smooth muscle cells is caused by a nonantisense mechanism", <i>Proc. Natl. Acad. Sci. USA</i> , April 25, 1995, Pages 4051-4055, Vol. 92, No. 9	
	C23	CHACE, J.H. et al., "Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12", <i>Clin. Immunol. Immunopathol.</i> , August 1997, Pages 185-193, Vol. 84, No. 2	
	C24	CONSTANT, P. et al., "Stimulation of Human $\gamma\delta$ T Cells by Nonpeptidic Mycobacterial Ligands", <i>Science</i> , April 8, 1994, Pages 267-270, Vol. 264	
	C25	CONSTANT, S.L. et al., "Induction of TH1 and TH2 CD4+ T Cell Responses: The Alternative Approaches", <i>Annu. Rev. Immunol.</i> , 1997, Pages 297-322, Vol. 15, Annual Reviews, Inc.	
	C26	COWDERY, J.S. et al., "Bacterial DNA induces NK cells to product IFN- γ in vivo and increases the toxicity of lipopolysaccharides", <i>J. Immunol.</i> , June 15, 1996, Pages 4570-4575, Vol. 156, No. 12, The American Association of Immunologists	
	C27	DAPIC, V. et al., "Antiproliferative Activity of G-Quartet Forming Oligonucleotides with Backbone and Sugar Modifications", <i>Proceedings of the AACR</i> , March 2001, 1 Page, Vol. 42, American Association of Cancer Research	
	C28	EIGLER, A. et al., "Taming TNF: strategies to restrain this proinflammatory cytokine", <i>Immunol. Today</i> , October 1997, Pages 487-492, Vol. 18, No. 10	
	C29	FEARON, D.T. et al., "The instructive role of innate immunity in the acquired immune response", <i>Science</i> , April 5, 1996, Pages 50-53, Vol. 272(5258)	
	C30	FINNAN, J.L. et al., "Developments in the phosphite-triester method of synthesis of oligonucleotides", <i>Nucleic Acids Research Symposium Series No. 7</i> , 1980, Pages 133-145, IRL Press Limited, UK	
	C31	GIORDANO, F.J. et al., "Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart", <i>Nat. Med.</i> , May 1996, Pages 534-539, Vol. 2, No. 5	
	C32	GOODMAN, M.G., "Mechanism of synergy between T cell signals and C8-substituted guanine nucleosides in humoral immunity: B lymphotropic cytokines induce responsiveness to 8-mercaptopguanosine", <i>J. Immunol.</i> , May 1, 1986, Pages 3335-3340, Vol. 136, No. 9, The American Association of Immunologists	
	C33	HADDEN, J.W., "Immunostimulants", <i>TIPS</i> , May 1993, Pages 169-174. Vol. 14, Elsevier Science Publishers Ltd. (UK)	
	C34	HAHM, K.B. et al., "Efficacy of Polyadenylic-Polyuridylic Acid in the Treatment of Chronic Active Hepatitis B", <i>Int. J. Immunopharmac.</i> , 1994, Pages 217-225, Vol. 16, No. 3, Elsevier Science Ltd., Great Britain	
	C35	HALPERN, M.D. et al., "Bacterial DNA induces murine interferon- γ production by stimulation of interleukin-12 and tumor necrosis factor- α ", <i>Cell Immunol. Article No. 0009</i> , January 10, 1996, Pages 72-78, Vol. 167, No. 1, Academic Press, Inc.	
	C36	HALPERN, M.D. et al., "In vitro inhibition of murine IFN gamma production by phosphorothioate deoxyguanosine oligomers", <i>Immunopharmacology</i> , February 1995, Pages 47-52, Vol. 29, No. 1	
	C37	HARRINGTON, D.G. et al., "Adjuvant Effects of Low Doses of a Nuclease-Resistant Derivative of Polyinosinic Acid-Polycytidylc Acid on Antibody Responses of Monkeys to Inactivated Venezuelan Equine Encephalomyelitis Virus Vaccine", <i>Infection and Immunity</i> , April 1970, Pages 160-166, Vol. 24	
	C38	HARTMANN, G. et al., "Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses in Vitro and in Vivo", <i>The Journal of Immunology</i> , 2000, Pages 1617-1624, Vol. 164, The American Association of Immunologists	
	C39	HERTL, M. et al., "Inhibition of interferon- γ -induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects", <i>J. Invest. Dermatol.</i> , May 1995, Pages 813-818, Vol. 104, No. 5, The Society of Investigative Dermatology, Inc.	
U	C40	ISNER, J.M. et al., "Clinical evidence of angiogenesis after arterial gene transfer of phVEGF ₁₆₅ in patient with ischaemic limb", <i>Lancet</i> , August 10, 1996, Pages 370-374, Vol. 348(9024)	
U	C41	KIMURA, Y. et al., "Binding of oligoguanylate to scavenger receptors is required for oligonucleotides to augment NK cell activity and induce IFN", <i>J. Biochem. (Tokyo)</i> , November 1994, Pages 991-994, Vol. 116, No. 5	

DEC 05 2001

C109

09/168,012

	C42	KRIEG, A.M. et al., "CpG motifs in bacterial DNA trigger direct B-cell activation", <i>Nature</i> , April 6, 1995, Pages 546-549, Vol. 374 (6522)	
	C43	KRIEG, A.M. et al., "Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs", <i>Antisense and Nucleic Acid Drug Dev.</i> , Summer 1996, Pages 133-139, Vol. 6, No. 2, Mary Ann Liebert, Inc.	
	C44	KRIEG, A.M. "An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA", <i>J. Lab. Clin. Med.</i> , August 1996, Pages 128-133, Vol. 128, No. 2	
	C45	KRIEG, A.M. et al., "The role of CpG dinucleotides in DNA vaccines", <i>Trends in Microbiology</i> , January 1998, Pages 23-27, Vol. 6, No. 1, Elsevier Science Ltd.	
	C46	KRIEG, A.M. et al., "Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs", <i>Proc. Natl. Acad. Sci. USA</i> , October 13, 1998, Pages 12631-12636, Vol. 95, No. 21	
	C47	KRIEG, A.M., "Leukocyte stimulation by oligodeoxynucleotides", Edited by Stein CA & Krieg AM., <i>Applied Antisense Oligonucleotide Technology</i> , 1998, Pages 431-448, Chapter 24, Wiley-Liss, New York	
	C48	KRIEGER, M. et al., "Structures and functions of multiligand lipoprotein receptors: macrophage scavenger receptors and LDL receptor-related protein (LRP)", <i>Annu. Rev. Biochem.</i> , 1994, Pages 601-637, Vol. 63, Annual Reviews, Inc.	
	C49	LANG, R. et al., "Guanosine-rich oligodeoxynucleotides induce proliferation of macrophage progenitors in cultures of murine bone marrow cells", <i>Eur. J. Immunol.</i> , 1999, Pages 3496-3506, Vol. 29, Wiley-VCH Verlag GmbH	
	C50	LEDERMAN, S. et al., "Polydeoxyguanine Motifs in a 12-mer Phosphorothioate Oligodeoxynucleotide Augment Binding to a v3 Loop of HIV-1 gp120 and Potency of HIV-1 Inhibition Independently of G-Tetrad Formation", <i>Antisense & Nucleic Acid Drug Development</i> , 1996, Pages 281-289, Vol. 6, Mary Ann Leibert, Inc.	
	C51	LEE, P.P. et al., "An Oligonucleotide Blocks Interferon- γ Signal Transduction", <i>Transplantation</i> , November 15, 1996, Pages 1297-1301, Vol. 62, No. 9, Williams & Wilkins, USA	
	C52	LIANG, H. et al., "Activation of human B cells by phosphorothioate oligodeoxynucleotides", <i>J. Clin. Invest.</i> , September 1, 1996, Pages 1119-1129, Vol. 98, No. 5, The American Society for Clinical Investigation, Inc.	
	C53	LIPFORD, G.B. et al., "Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines", <i>Eur. J. Immunol.</i> , December 1997, Pages 3420-3426, Vol. 27, No. 12, Wiley-VCH Verlag GmbH	
	C54	MACAYA, R.F. et al., "Thrombin-binding DNA aptamer forms a unimolecular quadruplex structure in solution", <i>Proc. Natl. Acad. Sci. USA</i> , April 1993, Pages 3745-3749, Vol. 90	
	C55	MACFARLANE, D.E. et al., "Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signaling step", <i>Immunology</i> , August 1997, Pages 586-593, Vol. 91, No. 4	
	C56	MACFARLANE, D.E. et al., "Antagonism of Immunostimulatory CpG-Oligodeoxynucleotides by Quinacrine, Chloroquine, and Structurally Related Compounds", <i>The Journal of Immunology</i> , 1998, Pages 1122-1131, Vol. 160, The American Association of Immunologists	
	C57	MEDZHITOY, R. et al., "Innate immunity: impact on the adaptive immune response", <i>Curr. Opin. Immunol.</i> , February 1997, Pages 4-9, Vol. 9, No. 1	
	C58	MESSINA, J.P. et al., "The influence of DNA structure on the in vitro stimulation of murine lymphocytes by natural and synthetic polynucleotide antigens", <i>Cellular Immunol.</i> , March 1993, Pages 148-157, Vol. 147, No. 1, Academic Press, Inc.	
	C59	MOSMANN, T.R. et al., "The expanding universe of T-cell subsets: Th1, Th2 and more", <i>Immunol. Today</i> , March 1996, Pages 138-146, Vol. 17, No. 3	
	C60	MUHLHAUSER, J. et al., "VEGF ₁₆₅ expressed by a replication-deficient recombinant adenovirus vector induces angiogenesis in vivo", <i>Circ. Res.</i> , December 1995, Pages 1077-1086, Vol. 77, No. 6	
	C61	PAUL, W.E., "Pleiotropy and redundancy: T cell-derived lymphokines in the immune response", <i>Cell</i> , May 19, 1989, Pages 521-524, Vol. 57, No. 4, Cell Press	
	C62	PISETSKY, D.S. et al., "Stimulation of in vitro proliferation of murine lymphocytes by synthetic oligodeoxynucleotides", <i>Mol. Biol. Rep.</i> , October 1993, Pages 217-221, Vol. 18, No. 3, Kluwer Academic Publishers, Belgium	
	C63	PISETSKY, D.S., "The influence of base sequence on the immunostimulatory properties of DNA", <i>Immunol. Res.</i> , 1999, Pages 35-46, Vol. 19, No. 1, Humana Press, Inc.	
	C64	RAMANATHAN, M. et al., "Characterization of the oligodeoxynucleotide-mediated inhibition of interferon- γ -induced major histocompatibility complex class I and intercellular adhesion molecule-1", <i>J. Biol. Chem.</i> , October 7, 1994, Pages 24564-24574, Vol. 269, No. 40, The American Society for Biochemistry and Molecular Biology, Inc., USA	
	C65	RAMANATHAN, M. et al., "Inhibition of interferon- γ -induced major histocompatibility complex class I expression of certain oligodeoxynucleotides", <i>Transplantation</i> , February 27, 1994, Pages 612-615, Vol. 57, No. 4, Williams & Wilkins, USA	



09/268,012

	C66	RAZ, E. et al., "Prefential induction of a Th1 immune response and inhibition of specific IgE antibody formation by plasmid DNA immunization", <i>Proc. Natl. Acad. Sci. USA</i> , May 1996, Pages 5141-5145, Vol. 93	
	C67	ROMAN, M. et al., "Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants", <i>Nat. Med.</i> , August 1997, Pages 849-854, Vol. 3, No. 8	
	C68	SATO, Y. et al., "Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization", <i>Science</i> , July 19, 1996, Pages 352-354, Vol. 273	
	C69	SCHAPER, W. et al., "Molecular mechanisms of coronary collateral vessel growth", <i>Circ. Res.</i> , November 1996, Pages 911-919, Vol. 79, No. 5, American Heart Association, Inc.	
	C70	SCHAPER, W. et al., "Therapeutic targets in cardiovascular disorders", <i>Curr. Opin. Biotechnol.</i> , December 1996, Pages 635-640, Vol. 7, No. 6, Current Biology, Inc.	
	C71	SPARWASSER, T. et al., "Bacterial DNA causes septic shock", <i>Nature</i> , March 27, 1997, Pages 336-337, Vol. 386(6623)	
	C72	SPARWASSER, T. et al., "Macrophages sense pathogens via DNA motifs: induction of tumor necrosis factor- α -mediated shock", <i>Eur. J. Immunol.</i> , July 1997, Pages 1671-1679, Vol. 27, No. 7, VCH Verlagsgesellschaft mbH	
	C73	SPARWASSER, T. et al., "Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells", <i>Eur. J. Immunol.</i> , June 1998, Pages 2045-2054, Vol. 28, No. 6, Wiley-VCH Verlag GmbH	
	C74	STACEY, K.J. et al., "Macrophages ingest and are activated by bacterial DNA", <i>J. Immunol.</i> , September 1, 1996, Pages 2116-2122, Vol. 157, No. 5, The American Society of Immunologists	
	C75	SUN, S. et al., "Multiple effects of immunostimulatory DNA on T cells and the role of type I interferons", <i>Springer Semin Immunopathol.</i> , 2000, Pages 77-84, Vol. 22, Springer-Verlag	
	C76	TALMADGE, J.E. et al., "Immuomodulatory Effects in Mice of Polyinosinic-Polycytidylc Acid Complexed with Poly-L-lysine and Carboxymethylcellulose", <i>Cancer Research</i> , March 1985, Pages 1058-1065, Vol. 45	
	C77	TREMBLEAU, S. et al., "The role of IL-12 in the induction of organ-specific autoimmune diseases", <i>Immunol. Today</i> , August 1995, Pages 383-386, Vol. 16, No. 8	
	C78	TOMASI, M. et al., "Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization", <i>Eur. J. Immunol.</i> , 1997, Pages 2720-2725, Vol. 27, Wiley-VCH Verlag	
	C79	WANG, Q. et al., "Second-generation adenovirus vectors", <i>Nat. Med.</i> , June 1996, Pages 714-716, Vol. 2, No. 6	
	C80	WLOCH, M.K. et al., "The influence of DNA sequence on the immunostimulatory properties of plasmid DNA vectors", <i>Hum. Gene. Ther.</i> , July 1, 1998, Pages 1439-1447, Vol. 9, No. 10, Mary Ann Liebert, Inc.	
	C81	WYATT, J.R. et al., "Combinatorially selected guanosine-quartet structure is a potent inhibitor of human immunodeficiency virus envelope-mediated cell fusion", <i>Proc. Natl. Acad. Sci. USA</i> , February 15, 1994, Pages 1356-1360, Vol. 91, No. 4	
	C82	YAKUBOV, L.A. et al., "Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?", <i>Proc. Natl. Acad. Sci. USA</i> , September 1989, Pages 6454-6458, Vol. 86, No. 17	
	C83	YAMAMOTO, S. et al., "In vitro augmentation of natural killer cell activity and production of interferon- α/β and - γ with deoxyribonucleic acid fraction from <i>Mycobacterium bovis BCG</i> ", <i>Jpn. J. Cancer Res. (Gann)</i> , July 1988, Pages 866-873, Vol. 79, No. 7	
	C84	YASWEN, P. et al., "Effects of sequence of thioated oligonucleotides on cultured human mammary epithelial cells", <i>Antisense Res. Dev.</i> , Spring 1993, Pages 67-77, Vol. 3, No. 1, Mary Ann Liebert, Inc. Publishers	
	C85	ZHAO, Q. et al., "Site of Chemical Modifications in CpG Containing Phosphorothioate Oligodeoxynucleotide Modules its Immunostimulatory Activity", <i>Bioorg. Med. Chem. Lett.</i> , December 20, 1999, Pages 3453-3458, Vol. 9, No. 24	

EXAMINER

Dahr

DATE CONSIDERED

8/1/02

#EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).